Kisspeptin as a Therapeutic
Kisspeptin, Upstream HPG Stimulation for Low Desire
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not FDA-approved; research-stage
Reference only. Not medical advice.
What can go wrong
In the published small trials kisspeptin was reported as well tolerated with no significant side effects, but the safety database is tiny and short-term. Any anti-aging or libido product sold as 'kisspeptin' outside a trial is unregulated, of unverified content, and not supported by approval data.
This is something to take to a clinician. The Atlas can tell you what is known about kisspeptin as a therapeutic in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Kisspeptin is a hypothalamic neuropeptide that sits at the top of the hypothalamic-pituitary-gonadal (HPG) axis, triggering GnRH release and thereby downstream LH, FSH, and testosterone. Imperial College London researchers have studied it as a potential treatment for low sexual desire. It is investigational only, there is no approved kisspeptin product and human studies remain small.
The master switch above the hormone axis, promising in early trials, not a product yet.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Kisspeptin acts on KISS1R (GPR54) receptors on hypothalamic GnRH neurons, driving pulsatile GnRH secretion and thereby LH/FSH release and gonadal steroidogenesis. Trials also reported effects on brain regions involved in sexual processing, suggesting both a hormonal and a central-behavioral component.
Why it is not a product
The widely cited JAMA Network Open trials enrolled only 32 men and 32 women with HSDD and measured surrogate outcomes (brain activation, penile tumescence, self-reported feelings) over short exposures. These are encouraging proof-of-concept signals, not evidence of a durable clinical treatment, and no larger registrational program has reported.
Safety in detail
Kisspeptin is investigational. It is not an approved therapy, and products marketed as kisspeptin are unregulated and of unverified content. Use should occur only within supervised clinical research.
What people get wrong
Often saidKisspeptin is a proven libido drug you can buy
ActuallyIt is an investigational neuropeptide with only small short-term human trials. There is no approved kisspeptin therapy.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Role
- Stimulates GnRH at the top of the HPG axis
- Lead research group
- Imperial College London (Dhillo, Comninos)
- Stage
- Small randomized trials
- Approved product
- None
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Kisspeptin as a Therapeutic. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Kisspeptin in men with HSDD (JAMA Netw Open)2023
n=32; kisspeptin increased sexual-brain-network activation and penile tumescence (reported up to ~56% increase in rigidity) vs placebo; well tolerated
Kisspeptin in women with HSDD (JAMA Netw Open)2022
n=32; enhanced sexual-brain processing and self-reported sexual response vs placebo